# Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

> **NCT01568580** · PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 71 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** GreenGene

## Key facts

- **NCT ID:** NCT01568580
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2012-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568580, "Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01568580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*